Fundraising FoxAnagin
Indianapolis, US · Founded 2013 · 1 known investors
Find your way into Anagin
Sign up to see every warm intro you have to Anagin
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Anagin team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.
Founders & leadership
JG
Jaswant GiddaExecutiveJaswant Gidda is an executive and director at Anagin, a drug discovery company focused on medicinal chemistry and preclinical research. He has expertise in regulatory affairs, toxicology, and product development across CNS, gastrointestinal, metabolic, and neurodegenerative disease areas.
JS
James SchulzExecutive
YL
Yvonne LaiNamed on SEC filing
DF
Dr. Fowler
DF
Dr. Florio
Board
ND
Nora DohertyBoard director
DS
Derek SmallBoard director
AS
Anantha ShekharBoard director
FF
Frank FrenchBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.4M disclosed across 2 rounds · 2016–2018
▶$1.3MraisedJun 2018 · 20 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedJun 2018 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anantha ShekharDirector
- Derek SmallDirector
- Frank FrenchDirector
- Yvonne LaiExecutive Officer
- Jaswant GiddaExecutive Officer, Director
- James SchulzExecutive Officer
- Nora DohertyDirector
- Offering amount
- $1.4M
- Amount sold
- $1.3M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3MraisedApr 2017 · 23 investors · PharmaceuticalsRule 506(b)
▶$3MraisedApr 2017 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nora DohertyDirector
- Derek SmallDirector
- Yvonne LaiExecutive Officer
- Anantha ShekharDirector
- Jaswant GiddaExecutive Officer, Director
- James SchulzExecutive Officer
- Frank FrenchDirector
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
OragenicsOragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
WalgreensWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
1MgThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
Companies working in the same space as Anagin.
In the news
Frequently asked questions
- What does Anagin do?
- A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.
- Who are Anagin's investors?
- Anagin's investors include EcoR1 Capital.
- How much funding has Anagin raised?
- Anagin has disclosed $4.4M raised across 2 rounds.
- Where is Anagin headquartered?
- Anagin is headquartered in Indianapolis, US.